WO2005079748A3 - Pharmaceutical preparation for sustained release of a pharmaceutically active ingredient - Google Patents
Pharmaceutical preparation for sustained release of a pharmaceutically active ingredient Download PDFInfo
- Publication number
- WO2005079748A3 WO2005079748A3 PCT/EP2005/001154 EP2005001154W WO2005079748A3 WO 2005079748 A3 WO2005079748 A3 WO 2005079748A3 EP 2005001154 W EP2005001154 W EP 2005001154W WO 2005079748 A3 WO2005079748 A3 WO 2005079748A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- active ingredient
- pharmaceutically active
- sustained release
- pharmaceutical preparation
- weight
- Prior art date
Links
- 239000004480 active ingredient Substances 0.000 title abstract 4
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract 3
- 238000013268 sustained release Methods 0.000 title abstract 3
- 239000012730 sustained-release form Substances 0.000 title abstract 3
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 abstract 2
- 239000011248 coating agent Substances 0.000 abstract 2
- 238000000576 coating method Methods 0.000 abstract 2
- 229920001577 copolymer Polymers 0.000 abstract 2
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 abstract 2
- SSONCJTVDRSLNK-UHFFFAOYSA-N 2-methylprop-2-enoic acid;hydrochloride Chemical compound Cl.CC(=C)C(O)=O SSONCJTVDRSLNK-UHFFFAOYSA-N 0.000 abstract 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 abstract 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 abstract 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200400338A ES2241478B1 (en) | 2004-02-13 | 2004-02-13 | PHARMACEUTICAL PREPARATION FOR THE SUSTAINED RELEASE OF A PHARMACEUTICALLY ACTIVE PRINCIPLE. |
ESP200400338 | 2004-02-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005079748A2 WO2005079748A2 (en) | 2005-09-01 |
WO2005079748A3 true WO2005079748A3 (en) | 2006-06-08 |
Family
ID=34878429
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2005/001154 WO2005079748A2 (en) | 2004-02-13 | 2005-02-04 | Pharmaceutical preparation for sustained release of a pharmaceutically active ingredient |
Country Status (2)
Country | Link |
---|---|
ES (1) | ES2241478B1 (en) |
WO (1) | WO2005079748A2 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005067887A2 (en) | 2004-03-24 | 2005-07-28 | Actavis Group | Formulations of ramipril |
US8007827B2 (en) * | 2004-04-02 | 2011-08-30 | Impax Laboratories, Inc. | Pharmaceutical dosage forms having immediate release and/or controlled release properties |
WO2007002518A1 (en) * | 2005-06-23 | 2007-01-04 | Spherics, Inc. | Delayed release or extended-delayed release dosage forms of pramipexole |
EP1810668A1 (en) * | 2006-01-23 | 2007-07-25 | LEK Pharmaceuticals D.D. | Coated formulations containing tolterodine tartrate |
JP2007308479A (en) | 2006-04-20 | 2007-11-29 | Shin Etsu Chem Co Ltd | Solid-dispersed substance preparation |
JP2007308480A (en) * | 2006-04-20 | 2007-11-29 | Shin Etsu Chem Co Ltd | Solid preparation containing enteric solid dispersion |
WO2008027557A2 (en) | 2006-08-31 | 2008-03-06 | Spherics, Inc. | Topiramate compositions and methods of enhancing its bioavailability |
ES2312308T3 (en) | 2006-11-17 | 2013-03-26 | Supernus Pharmaceuticals, Inc. | Topiramate sustained release formulations |
US8871275B2 (en) | 2007-08-08 | 2014-10-28 | Inventia Healthcare Private Limited | Extended release compositions comprising tolterodine |
KR101322000B1 (en) * | 2008-09-03 | 2013-10-29 | 이엘씨 매니지먼트 엘엘씨 | Compositions comprising solid particles encapsulated in a cross-linked silicone matrix, and methods of making the same |
CN102579367B (en) * | 2012-03-23 | 2014-03-12 | 中国人民解放军军事医学科学院毒物药物研究所 | Topiramate sustained-release drug composition, method for preparing same and application of Topiramate sustained-release drug composition |
CN103316026B (en) | 2012-03-23 | 2016-05-11 | 中国人民解放军军事医学科学院毒物药物研究所 | Contain joint product of Phentermine and Topiramate and preparation method thereof |
EP2829270B1 (en) | 2012-03-23 | 2020-11-11 | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China | Joint product containing synephrine and topiramate |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
JP6389889B2 (en) * | 2013-08-06 | 2018-09-12 | タスリー・ファーマシューティカル・グループ・カンパニー・リミテッドTasly Pharmaceutical Group Co., Ltd. | Application of andrographolide in pharmaceutical preparations for the treatment of inflammatory bowel disease, andrographolide enteric target micropellets and method for producing the same |
DE102018129419A1 (en) * | 2018-11-22 | 2020-05-28 | Johannes Gutenberg-Universität Mainz | Acrylate copolymer for pharmaceutical applications |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0720473B1 (en) * | 1993-09-23 | 1998-11-11 | Dr. Falk Pharma Gmbh | Budesonide pellets with a controlled release pattern and process for producing them |
US6039979A (en) * | 1999-01-13 | 2000-03-21 | Laboratoires Prographarm | Multiparticulate pharmaceutical form with programmed and pulsed release and process for its preparation |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT93637A (en) * | 1989-04-20 | 1990-11-20 | Procter & Gamble | METHOD FOR THE TREATMENT OF INTESTINAL / COLONIC FUNCTIONAL DISORDERS, ESPECIALLY THE INTESTINAL IRRITATION SYNDROME |
AR023700A1 (en) * | 1998-11-12 | 2002-09-04 | Smithkline Beecham Plc | A PROCEDURE TO PREPARE A PHARMACEUTICAL COMPOSITION THAT INCLUDES AN INSULIN SENSITIZER |
US20030153607A1 (en) * | 1998-11-12 | 2003-08-14 | Smithkline Beecham P.L.C. | Novel composition and use |
EP1206250A2 (en) * | 1999-08-26 | 2002-05-22 | ELAN CORPORATION, Plc | Pharmaceutical formulations with different release times |
-
2004
- 2004-02-13 ES ES200400338A patent/ES2241478B1/en not_active Expired - Fee Related
-
2005
- 2005-02-04 WO PCT/EP2005/001154 patent/WO2005079748A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0720473B1 (en) * | 1993-09-23 | 1998-11-11 | Dr. Falk Pharma Gmbh | Budesonide pellets with a controlled release pattern and process for producing them |
US6039979A (en) * | 1999-01-13 | 2000-03-21 | Laboratoires Prographarm | Multiparticulate pharmaceutical form with programmed and pulsed release and process for its preparation |
Non-Patent Citations (3)
Title |
---|
AKBUGA JULIDE: "Effect of microsphere size and formulaton factors on drug release from controlled-release furosemide microspheres", DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, vol. 17, no. 4, 1991, pages 593 - 607, XP008062720 * |
PONGPAIBUL Y, PRICE JC, WHITWORTH CW: "Preparation and evaluation of controlled release indomethacin microspheres", DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, vol. 10, no. 10, 1984, pages 1597 - 1616, XP008062731 * |
TSANKOV S, LAMBOV N; MINKOV E: "Regulation of tetracycline hydrochloride release from polyacrylate microspheres.", PHARMAZEUTISCHE INDUSTRIE, vol. 57, no. 12, 1995, pages 1044 - 1047, XP008062723 * |
Also Published As
Publication number | Publication date |
---|---|
ES2241478A1 (en) | 2005-10-16 |
WO2005079748A2 (en) | 2005-09-01 |
ES2241478B1 (en) | 2006-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005079748A3 (en) | Pharmaceutical preparation for sustained release of a pharmaceutically active ingredient | |
WO2005046649A3 (en) | Multilayer pharmaceutical dosage form containing a substance that acts in a modulatory manner with regard to the release of active substances | |
WO2007006353A3 (en) | Use of a partially neutralized, anionic (meth)acrylate copolymer as a coating for the production of a medicament releasing active substance at reduced ph values | |
WO2000019984A3 (en) | Coated medicament forms with controlled active substance release | |
UA93530C2 (en) | Composition with sustained release of an active ingredient, process for the preparation and use thereof | |
EP2158905A3 (en) | Composition for the Transdermal Delivery of Fentanyl | |
CA2370067A1 (en) | Pharmaceutical dosage forms for controlled release producing at least a timed pulse | |
WO2005070462A3 (en) | Compositions comprising (s)-amlodipine and an angiotensin receptor blocker and methods of their use | |
WO2004062577A3 (en) | Two or more enteric materials to regulate drug release | |
HK1054195A1 (en) | Coating and binding agent for pharmaceutical formulations with improved storage stability. | |
IL167334A (en) | Multilayer dosage forms which contain active substances and which comprise a neutral core and an inner and outer coating consisting of methacrylate copolymers and methacrylate monomers | |
WO2005041968A3 (en) | Once-a-day, oral, controlled-release, oxycodone dosage forms | |
WO2007011619A3 (en) | Highly bioavailable oral delayed release dosage forms of o-desmethylvenlafaxine succinate | |
CA2317106A1 (en) | Method and composition of an oral preparation of itraconazole | |
WO2006010394A3 (en) | Medicament in a multilayer form | |
AU2002254036A1 (en) | Taste masked pharmaceutical compositions | |
WO2004112756A8 (en) | Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient | |
WO2008084698A1 (en) | Tacrolimus sustained release pharmaceutical composition | |
WO2005099666A3 (en) | Delayed release formulations of 6-mercaptopurine | |
WO2006062933A3 (en) | Stable compositions of fenofibrate with fatty acid esters | |
CA2470656A1 (en) | Corticotropin releasing factor 2 receptor agonists | |
NZ535750A (en) | Film coating for controlled release of pharmaceutical drugs | |
WO2003099203A3 (en) | Enteric coated caffeine tablet | |
EP1699448A4 (en) | Methods of administering 3,3,14,14 tetramethyl hexadecane 1,16 dioic acid | |
BENBACERING | Death of Living Buddha Bomi |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase |